Navigation Links
Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial

Vical Incorporated announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.

The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology (ASM) 2006 Biodefense Research Meeting in Washington, D.C., by Julie E. Martin, D.O., a trial investigator and research scientist at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC), which developed the vaccine. The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine.

"The high rates of immune responses at all dose levels in this initial human Ebola vaccine study support continued development of this vaccine and further evaluation of our technology for potential additional biodefense and emerging disease applications," said David C. Kaslow, M.D., Vical's Chief Scientific Officer, "particularly where antibody responses may be protective. Our processes allow rapid development and manufacturing of vaccines without handling potentially dangerous pathogens."

The vaccine used in the Phase 1 trial vaccine included three plasmids (closed loops of DNA), one each encoding the surface glycoprotein (GP) from the Zaire strain of Ebola, GP from the Sudan/Gulu strain, and the internal nucleoprotein (NP) from the Zaire strain. Subjects received three doses of vaccine or placebo at one-month intervals via intramuscular needleless injection. Three coh
'"/>

Source:Porter Novelli, Life Sciences


Page: 1 2

Related biology news :

1. Study Links Ebola Outbreaks To Animal Carcasses
2. Scientists discover how Ebola virus infects cells
3. Ebola virus: from wildlife to dogs
4. Poaching, logging, and outbreaks of Ebola threaten central African gorillas and chimpanzees
5. Gene-specific Ebola therapies protect non-human primates from lethal disease
6. Gorilla susceptibility to Ebola virus: the cost of sociality
7. Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease
8. Pattern of human Ebola outbreaks linked to wildlife and climate
9. Ebola-outbreak kills 5000 gorillas
10. Ebola outbreaks killing thousands of gorillas and chimpanzees
11. Research advances quest for HIV-1 vaccine
Post Your Comments:
(Date:8/20/2014)... Multiple fires are visible in in this image of ... Many of these were most likely intentionally set in ... of a forest or stand of trees where the ... of deforestation include conversion of forestland to farms, ranches, ... the dark green of the Amazon Rainforest in the ...
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... found that new disease pathways involving more than one ... rare genetic disorder in which fatty substances called glycosphingolipids ... pain, and increased risk of cancer and Parkinson,s disease. ... expensive and more effective ways to treat the disorder, ...
... release is available in French . , Scientists ... McGill University have discovered that our brains have the ability ... specially-coded sounds, without any visual or tactile input. Not only ... the brain and how it perceives the world around us, ...
... Inhaling nitric oxide appears to safely and effectively ... researchers report., A study of 18 patients in Atlanta, ... oxide for four hours had better pain control than ... C. Alvin Head, chairman of the Department of Anesthesiology ...
Cached Biology News:Cheaper, more effective treatment of type 1 Gaucher disease possible 2See no shape, touch no shape, hear a shape? 2Inhaling nitric oxide eases pain crises in sickle cell patients 2
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group finds that the vascular ... Russia , India and ... 2013, roughly equal to the size of the United ... market will experience much faster growth as a result of strong ... Other key findings from Decision Resources Group,s coverage of the ...
(Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
(Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Sept. 15 Epeius Biotechnologies,Corporation today announced that ... has been highlighted in a recent NEWS article,published ... (JNCI, Sept. 9,2008). The article, authored by Vickie ... medicine that may succeed where small,molecules and proteins ...
... Enobia Pharma, an emerging biotech,company focused ... presented pre-clinical data demonstrating that its enzyme,replacement ... bones that,have already been severely weakened by ... with Enobia,s product ENB-0040, significantly,increases survival and ...
... Offers Industry Dialogue, Commentary and How-To, ... Collaboration, PALO ALTO, Calif., Sept. 15 ... strategist and communicator, has,launched a new website, ... and communicators can share thinking, gain insights and,connect ...
Cached Biology Technology:Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 2Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice 3
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... mix (Thermoprime Plus DNA Polymerase with a ... times higher fidelity than standard Taq DNA ... DNA polymerase, Amplifies DNA templates >20kb, Concentration: ... PCR for cloning and mutagenesis We are ...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
Biology Products: